Compare SPRU & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRU | AYTU |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 27.4M |
| IPO Year | 2019 | 2015 |
| Metric | SPRU | AYTU |
|---|---|---|
| Price | $1.46 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | ★ 155.0K | 42.3K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.30 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | $23,194,000.00 | ★ $27,632,080.00 |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | N/A | $27.98 |
| P/E Ratio | $73.50 | ★ N/A |
| Revenue Growth | 48.68 | ★ 277.47 |
| 52 Week Low | $1.46 | $1.80 |
| 52 Week High | $6.75 | $3.07 |
| Indicator | SPRU | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 32.80 | 43.11 |
| Support Level | N/A | $1.89 |
| Resistance Level | $1.90 | $2.34 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 0.00 | 27.40 |
Spruce Power Holding Corp is an owner and operator of distributed solar energy assets across the United States (the U.S.), offering subscription-based services to home solar assets and customer contracts, making renewable energy more accessible to everyone. The Company's customers are homeowners and the Company's core solar service offerings generate revenues through, the sale of electricity generated by its home solar energy systems to homeowners, third-party contracts to sell solar renewable energy credits (SRECs) generated by the solar energy systems for fixed prices and the servicing of those agreements for other institutional owners of home solar energy systems.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.